Since the publication of the first WHO hepatitis A vaccine position paper in 2000, and the updated paper in 2012, there have been changes in the epidemiological features of hepatitis A virus (HAV) infection in several countries, increased supply of hepatitis A vaccines, and new evidence on their public health benefits and their potential for long-term protection. The updated systematic evidence review has focussed specifically on longer term follow up studies (3 to 7 years and > 7 year follow up) including efficacy, effectiveness and safety data of multidose and single dose regimens of inactivated and live attenuated hepatitis A vaccines in children or adults vaccinated during childhood. In addition, population impact, cost effectiveness and economic impact and outcomes of mathematical modelling were assessed. The evidence generated from the 2012 systematic review which also included adults, and examined short term efficacy, effectiveness, and safety data as well as studies on post exposure prophylaxis has also been considered in this update.
- SAGE background document
- Hepatitis A
